Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major
AbstractTreatment of chronic hepatitis C virus [HCV] infection in transfusion-dependent betathalassaemia major patients is complicated by existing hepatic siderosis and the fear of ribavirinassociated haemolysis. We evaluated the efficacy and side-effects of combination interferon-alpha [INF] and ribavirin therapy for HCV-infected thalassaemia patients. A total of 17 patients were enrolled [10 nonresponders to INF monotherapy, 7 naive to treatment, mean age 23.1 years] and they received 12 months of combination therapy. The sustained virological response rate 6 months after treatment was 58.8%. Blood transfusion requirements during treatment temporarily increased by 36.6%. Combination therapy was tolerated by, and may be useful for, HCV-infected thalassaemia major patients
Saffar, M.J., Saffar, H., Khalilian, A.R. & Naqshvar, F. (2009). Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major. EMHJ - Eastern Mediterranean Health Journal, 15 (4), 785-791, 2009 http://www.who.int/iris/handle/10665/117699
JournalEMHJ - Eastern Mediterranean Health Journal, 15 (4), 785-791, 2009
MetadataShow full item record
Showing items related by title and MeSH subject.
Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients Kishk, R.; Aboul Atta, H.; Ragheb, M.; Kamel, M.; Metwally, L.; Nemr, N. (2014)Chronic hepatitis C virus [HCV]infection combined with occult hepatitis B virus [HBV]infection has been associated with increased risk of hepatitis, cirrhosis and hepatocellular carcinoma.This study aimed to determine the prevalence of occult HBV infection among Egyptian chronic HCV patients, the genotype and occurrence of surface gene mutations of HBV and the impact of co-infection on early response to treatment.The study enrolled 162 chronic HCV patients from Ismailia Fever Hospital, Egypt, who were HBV surface antigen-negative.All patients ...
Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection Al Enzi, S.A.; Ismail, W.A.; Alsurayei, S.A.; Ismail, A.E. (2011)Few studies have been conducted in the Eastern Mediterranean region on chronic hepatitis C virus [HCV] infection with reference to genotypes. We investigated the response to standard combination therapy [pegylated interferon/ribavirin] of different genotypes of HCV in Kuwaiti patients and factors that could be associated with sustained virological response [SVR]. The records of all Kuwaiti patients treated for chronic HCV between January 2003 and May 2009 were retrospectively identified and reviewed. Of 108 patients studied, 27.8% were infected ...